Press Releases

Filters
May 14, 2002

Debiopharm S.A. reports study revealing that EPI-HNE4 offers protection against acute lung injury

Read more
March 24, 2002

Debiopharm SA a acquis un nouveau bâtiment à Lausanne et projette de déménager vers la fin 2004

Read more
March 17, 2002

H3 Pharma Licenses in Phase II Product for Stomach Cancer and Acquires Stake in a Human mAb Discovery Company Specializing…

Read more
July 5, 2001

Swiss drug developer Debiopharm announces FDA approval of Trelstar TM LA for therapeutic use

Read more
April 14, 2001

Debiopharm and Aurigene sign agreement for the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology…

Read more
February 13, 2001

Dyax Corp. and Debiopharm S.A. report initiation of phase II clinical trial with EPI-HNE-4 for cystic fibrosis

Read more
January 10, 2001

Swiss drug developer Debiopharm S.A. achieves another success in the development of molecules for theraeutic use

Read more